Lipidated peptide cuts neuropathic pain behaviors in mice by disrupting Nav1.8-Ank3
Unlike gabapentin, the peptide did not reduce animal mobility at the point of greatest pain relief, the Boston Children's team reports.
PR
By Priya Raman · Science Reporter
Oct 6 11:00 ETSource: Inside Precision Medicine
The wire
- 01Researchers in Clifford Woolf's lab developed a short lipidated peptide that blocks the Nav1.8 sodium channel's interaction with scaffolding protein ankyrin-3, reducing surface Nav1.8 in sensitized nociceptors; published in Cell Reports Medicine.
- 02In mouse models of neuropathic and inflammatory pain, treatment lowered spontaneous pain behavior and touch hypersensitivity while leaving acute pain responses in uninjured animals intact, a possible non-opioid route.
- 03Findings are preclinical, and the authors note the importance of the Nav1.8-Ank3 interaction still needs confirmation in humans.
From the source
Read at insideprecisionmedicine.comExperimental Peptide Quiets Chronic Pain Signals While Preserving Protective Pain
A new approach to treating chronic pain could potentially quiet abnormal pain signals without interfering with the body’s ability to sense injury, according to research from the laboratory of Clifford Woolf, PhD, at Boston Children’s Hospital’s F.M. Kirby Neurobiology Center.
